Rapt Therapeutics Inc Reports Results For The Quarter Ended In December: Earnings Summary

Rapt Therapeutics

12/03/2024 13:31

* RAPT Therapeutics Inc  RAPT.OQ  reported a quarterly
adjusted
loss of 80 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -64 cents.  The mean expectation of eleven analysts for
the quarter was for a loss of 86 cents per share. Wall Street
expected results to range from -92 cents to -79 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * RAPT Therapeutics Inc's reported EPS for the quarter was a
loss
of 80 cents​.
    * The company reported a quarterly loss of $30.88 million.
    * RAPT Therapeutics Inc shares had fallen by 67.4% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for RAPT Therapeutics
Inc is $19.50 
This summary was machine generated from LSEG data March 12 at
01:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.86          -0.80          Beat
 Sep. 30 2023      -0.75          -0.82          Missed
 Jun. 30 2023      -0.78          -0.66          Beat
 Mar. 31 2023      -0.68          -0.76          Missed